Search results for "Antiretroviral drug"

showing 10 items of 14 documents

Apoptosis of Hepatocytes: Relevance for HIV-Infected Patients under Treatment.

2021

Due to medical advances over the past few decades, human immunodeficiency virus (HIV) infection, once a devastatingly mortal pandemic, has become a manageable chronic condition. However, available antiretroviral treatments (cART) cannot fully restore immune health and, consequently, a number of inflammation-associated and/or immunodeficiency complications have manifested themselves in treated HIV-infected patients. Among these chronic, non-AIDS (acquired immune deficiency syndrome)-related conditions, liver disease is one of the deadliest, proving to be fatal for 15–17% of these individuals. Aside from the presence of liver-related comorbidities, including metabolic disturbances and co-infe…

0301 basic medicineProgrammed cell deathChronic conditionantiretroviral drugs; apoptosis; hepatic cell death; HIV; liver; toxicityInflammationApoptosisHIV InfectionsReviewliverModels Biological03 medical and health sciencesLiver disease0302 clinical medicineImmune systemAntiretroviral Therapy Highly ActivemedicineHumans030212 general & internal medicinelcsh:QH301-705.5antiretroviral drugsImmunodeficiencybusiness.industryapoptosisHIVtoxicityGeneral Medicinemedicine.diseasehepatic cell death030104 developmental biologylcsh:Biology (General)LiverApoptosisImmunologyUnfolded protein responseHepatocytesmedicine.symptombusinessCells
researchProduct

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved.

2021

Due to the improved effectiveness and safety of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection has become a manageable, chronic condition rather than a mortal disease. However, HIV patients are at increased risk of experiencing non-AIDS-defining illnesses, with liver-related injury standing out as one of the leading causes of death among these patients. In addition to more HIV-specific processes, such as antiretroviral drug-related toxicity and direct injury to the liver by the virus itself, its pathogenesis is related to conditions that are also common in the general population, such as alcoholic and non-alcoholic fatty liver disease, viral hepatitis, and age…

0301 basic medicinehepatotoxicityNevirapineEfavirenzQH301-705.5030106 microbiologyEtravirinecARTReviewBioinformaticsliver03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicineDoravirinemedicineAnimalsHumans030212 general & internal medicineBiology (General)antiretroviral drugsbusiness.industryFatty livervirus diseasesHIVGeneral Medicinemedicine.diseasechemistryRilpivirineChronic DiseaseReverse Transcriptase InhibitorsDrug Therapy CombinationDILIChemical and Drug Induced Liver InjuryViral hepatitisbusinessmedicine.drugCells
researchProduct

Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells

2010

BACKGROUND AND PURPOSE Efavirenz (EFV) is widely used in the treatment of HIV-1 infection. Though highly efficient, there is growing concern about EFV-related side effects, the molecular basis of which remains elusive. EXPERIMENTAL APPROACH In vitro studies were performed to address the effect of clinically relevant concentrations of EFV (10, 25 and 50 mu M) on human hepatic cells. KEY RESULTS Cellular proliferation and viability were reduced in a concentration-dependent manner. Analyses of the cell cycle and several cell death parameters (chromatin condensation, phosphatidylserine exteriorization, mitochondrial proapoptotic protein translocation and caspase activation) revealed that EFV tr…

CyclopropanesMalehepatotoxicityCarcinoma HepatocellularTime FactorsAnti-HIV AgentsCell SurvivalApoptosisMitochondria LiverPhosphatidylserinesAntioxidantsSuperoxidesHumansChromansantiretroviral drugsCell Proliferationreactive oxygen speciesDose-Response Relationship DrugCell CycleLiver NeoplasmsChromatin Assembly and DisassemblyResearch PapersGlutathioneBenzoxazinesmitochondriaOxidative Stressside effectscell deathLiverAlkynesFemaleEfavirenzApoptosis Regulatory ProteinsHeLa Cells
researchProduct

Different origin of adipogenic stem cells influences the response to antiretroviral drugs

2015

Lipodystrophy (LD) is a main side effect of antiretroviral therapy for HIV infection, and can be provoked by nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs). LD exists in different forms, characterized by fat loss, accumulation, or both, but its pathogenesis is still unclear. In particular, few data exist concerning the effects of antiretroviral drugs on adipocyte differentiation. Adipose tissue can arise either from mesenchymal stem cells (MSCs), that include bone marrow-derived MSCs (hBM-MSCs), or from ectodermal stem cells, that include dental pulp stem cells (hDPSCs). To analyze whether the embryonal origin of adipocytes might impact the occurrence of d…

LipodystrophyPharmacologyBiologyAntiviral Agentschemistry.chemical_compoundFatty acid bindingDental pulp stem cellsLipid dropletAdipocytemedicineAdipocytesReverse transcriptaseAnimalsHumansDental PulpInhibitorsStavudineMesenchymal stem cellMesenchymal Stem CellsCell BiologyProtease inhibitorsVirologyRetroviridaechemistryAdipogenesisAntiretroviral drugsStem cellAntiretroviral drugs; Inhibitors; Lipodystrophy; Protease inhibitors; Reverse transcriptasemedicine.drugRetroviridae Infections
researchProduct

Low Rate of Virological Failure and Maintenance of Susceptibility to HIV-1 Protease Inhibitors with First-Line Lopinavir/Ritonavir-Based Antiretrovir…

2010

Protease inhibitor (PI)-resistant HIV-1 has hardly ever been detected at failed boosted PI-based first-line antiretroviral regimens in clinical trials. However, this phenomenon has not been investigated in clinical practice. To address this gap, data from patients starting a first-line lopinavir/ritonavir (LPV/rtv)-based therapy with available baseline HIV-1 RNA load, a viral genotype and follow-up viral load after 3 and 6 months of treatment were extracted from the Italian Antiretroviral Resistance Cohort Analysis (ARCA) observational database. Based on survival analysis, 39 (7.1%) and 43 (7.8%) of the 548 examined patient cases had an HIV-1 RNA >500 and >50 copies/ml, respectively, after …

MaleLopinavir/ritonavirHIV Infectionsboosted protease inhibitorLopinavirCohort Studies0302 clinical medicineAntiretroviral Therapy Highly Activevirologic failureHIV InfectionTreatment Failure030212 general & internal medicinePyrimidinone0303 health scienceseducation.field_of_studylopinavir/ritonavirLopinavirViral LoadResistance mutationfirst-line antiretroviral therapyReverse Transcriptase Inhibitor3. Good healthTreatment OutcomeInfectious DiseasesRNA ViralReverse Transcriptase InhibitorsMedicineDrug Therapy CombinationFemaleSurvival AnalysiViral loadHumanmedicine.drugAnti-HIV AgentsPopulationPyrimidinones.Settore MED/17 - MALATTIE INFETTIVEEmtricitabinehuman immunodeficiency virus type 103 medical and health sciencesVirologyDrug Resistance Viralantiretroviral drug resistancemedicineHumansProtease inhibitor (pharmacology)educationHIV Protease InhibitorRitonavir030306 microbiologybusiness.industryAnti-HIV AgentHIV Protease InhibitorsSurvival AnalysisVirologyHIV-1RitonavirCohort Studiebusiness
researchProduct

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

2014

Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained con…

Malevirus strainResistanceHIV InfectionsDrug resistanceTHERAPYNucleoside Reverse Transcriptase InhibitorANTIRETROVIRAL DRUG-RESISTANCE0302 clinical medicineMedical microbiologyGenotypeMedicine and Health SciencesPrevalenceHIV Infection030212 general & internal medicineUNITED-KINGDOMPhylogeny0303 health sciencesCommunicable diseaseTransmission (medicine)adultvirus mutationUPDATED RECOMMENDATIONSvirus transmission3. Good healthEuropeInfectious Diseasesfemalerisk factorvirus resistanceFemaleNAIVE PATIENTSSOCIETY-USA PANELResearch ArticleHumanAdultmedicine.medical_specialtyGenotypeAnti-HIV AgentsVirusArticle03 medical and health sciencesSDG 3 - Good Health and Well-beingmaleMOLECULAR EPIDEMIOLOGYDrug Resistance Viralmedicineproteinase inhibitorHumansTransmissioncontrolled studyhumanmolecular phylogeny030304 developmental biologynonhumanMUTATIONSbusiness.industryAnti-HIV Agentnucleotide sequencenonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionVirologymajor clinical studyunindexed sequenceParasitology3121 General medicine internal medicine and other clinical medicineMutationHIV-1business
researchProduct

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

2011

Abstract Background HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed. Methods We analyzed patients of the Italian ARCA cohort starting a new cART from 1999 onwards either after virologic failure or as treatment-naïve. The time to virologic failure was the endpoint, from the 90th day after treatment start, defined as the firs…

OncologyMaleAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral LoadHIV InfectionsCohort Studies0302 clinical medicineANTIRETROVIRAL THERAPYMedicineHIV Infection030212 general & internal medicineTreatment Failure0303 health sciencesHealth PolicyMiddle AgedViral Load3. Good healthComputer Science ApplicationsCensoring (clinical trials)CohortCombinationlcsh:R858-859.7Drug Therapy CombinationFemaleViral loadHumanResearch ArticleCartAdultmedicine.medical_specialtyAnti-HIV AgentsHIV-1; antiretroviral therapyHealth InformaticsSettore MED/17 - MALATTIE INFETTIVElcsh:Computer applications to medicine. Medical informatics03 medical and health sciencesDrug TherapyInternal medicineHumansSurvival analysisProportional Hazards Models030306 microbiologybusiness.industryProportional hazards modelAdult; Anti-HIV Agents; Cohort Studies; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Proportional Hazards Models; Treatment Failure; Viral Load; Health Informatics; Health PolicyANTIRETROVIRAL DRUGSAnti-HIV AgentHIVGENOTYPESDiscontinuationRegimenImmunologyProportional Hazards ModelHIV-1Cohort StudiebusinessBMC Medical Informatics and Decision Making
researchProduct

Contamination of Surface Water and River Sediments by Antibiotic and Antiretroviral Drug Cocktails in Low and Middle-Income Countries: Occurrence, Ri…

2020

Presence of antimicrobial cocktails in the hydrological cycles is of interest because of their potential to mediate antimicrobial resistance within the natural environment. In this study, we determined the concentrations of selected antibiotics and antiretroviral drugs (ARVDs) in wastewater treatment plant (WWTP) effluent, effluent suspended particulate matter (SPM), surface waters and river sediments in Kenya in order to determine the extent of pollution within the sampled environment. Target analysis for the most common antibiotics and ARVDs was done. Sulfamethoxazole (SMX), ciprofloxacin (CIP), trimethoprim (TMP), norfloxacin (NOR), zidovidine (ZDV), lamivudine (3TC) and nevirapine (NVP)…

Pollutionlcsh:Hydraulic engineeringmedia_common.quotation_subjectGeography Planning and Development0207 environmental engineeringsedimentit02 engineering and technologyjätevesi010501 environmental sciencesAquatic Science01 natural sciencesBiochemistryantibioticslcsh:Water supply for domestic and industrial purposeslcsh:TC1-978Organic matterantimicrobial resistance020701 environmental engineeringEffluentwastewaterantiretroviral drugs0105 earth and related environmental sciencesWater Science and Technologymedia_commonchemistry.chemical_classificationantimikrobiset yhdisteetlcsh:TD201-500vesien saastuminensedimentsantibiootitlääkeaineetContaminationAntimicrobialsuspended particulate matter6. Clean waterchemistryWastewaterpintavesi13. Climate actionEnvironmental chemistryEnvironmental scienceSewage treatmentSurface waterWater
researchProduct

Removal of selected antibiotics and antiretroviral drugs during post‐treatment of municipal wastewater with UV, UV/chlorine and UV/hydrogen peroxide

2020

Active pharmaceutical ingredients (APIs) are only partially removed by convectional wastewater treatment plants. This study aimed at assessing the post‐treatment degradation of selected antibiotics and antiretroviral drugs by direct UV photolysis and advanced oxidation processes (UV/H2O2 and UV/Cl2) using low‐pressure mercury lamp. The rate of degradation largely followed pseudo first‐order reaction kinetics. Amongst the six studied APIs, sulfamethoxazole, ciprofloxacin and zidovudine were readily degraded by more than 90% using direct UV photolysis. Addition of Cl2 and H2O2 to the UV process led to an increase in the rate of degradation for all the compounds. The effectiveness UV/Cl2 proce…

advanced oxidation processEnvironmental Engineeringmedicine.drug_classAntibioticslääkeainejäämätchemistry.chemical_elementhydrogen peroxidejätevesiManagement Monitoring Policy and Lawchemistry.chemical_compoundantibiotics antiretroviral drugskloorivetyperoksidimedicineChlorinehapetus-pelkistysreaktioHydrogen peroxidepost‐treatmentwastewaterWater Science and Technologyjäteveden käsittelyAdvanced oxidation processyhdyskuntajätteetlääkeaineetPulp and paper industryPollutionbiohajoaminenUVchemistryWastewaterchlorinePost treatment
researchProduct

Evidence of an interplay between ER stress/UPR and mitochondria in human hepatic cells treated with the antiretroviral drug Efavirenz

2013

chemistry.chemical_compoundEfavirenzchemistrybusiness.industryPhysiology (medical)Hepatic stellate cellUnfolded protein responseMedicineAntiretroviral drugPharmacologyMitochondrionbusinessBiochemistryFree Radical Biology and Medicine
researchProduct